Sitemap
Posts
- Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care.
- ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer’s Disease
- ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer’s Disease Testing
- Broad AD/PD™ 2026 Validation Reinforces ALZpath pTau217 Antibody as Industry Benchmark for Blood-Based Alzheimer's Diagnosis
- ALZpath Commits to Eliminating the ‘D-Word’ to Reduce Stigma and Support Early Alzheimer’s Detection
- ALZpath-Powered Blood Test Enables Landmark Study on Growing Alzheimer’s Disease Prevalence
- ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer’s Disease Diagnostic Testing
- ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for 'Diagnostics Innovation of the Year'
- Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer's Disease Research, Diagnosis, and Treatment
- ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
- Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis
- ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
- ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
- ALZpath Appoints Mike Banville as CEO
- Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
- ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
- New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
- ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
- ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
- ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease
- Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
- New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain
- ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay
- ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
Pages
Team Members
- Micah Buehler
- Michael Weiner, MD
- Soeren Mattke, MD, DSc
- Sterling Johnson, PhD
- Jeff Dage, PhD
- Kaj Blennow, MD, PhD
- Irit Rappley, PhD
- Eric Reiman, MD
- Peter Snyder, PhD
- Jeff Cummings, MD, ScD(HC)
- Henrik Zetterberg, MD, PhD
- Harry Johns
- John Hensing, MD
- John Courtney
- Samantha L. Budd Haebelrein, PhD
- Jerre Stead
- Lee Honigberg
- Jacob Hunter
- Steve Haft
- Mike Banville